Investors & Media

Press Releases

Date Title and Summary Additional Formats
Toggle Summary ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WALTHAM, Mass. --(BUSINESS WIRE)--Feb. 1, 2022-- ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that on January 31, 2022 , the compensation committee of the Company’s Board of Directors granted
View HTML
Toggle Summary ImmunoGen Appoints Mimi Huizinga, MD, as Senior Vice President and Head of Medical Affairs
WALTHAM, Mass. --(BUSINESS WIRE)--Jan. 31, 2022-- ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that Mimi Huizinga , MD, MPH, FACP has been appointed Senior Vice President and Head of Medical Affairs.
View HTML
Toggle Summary ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WALTHAM, Mass. --(BUSINESS WIRE)--Jan. 3, 2022-- ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that on December 31, 2021 the compensation committee of the Company’s Board of Directors granted a
View HTML
Toggle Summary ImmunoGen Announces Webcast of Presentation and Q&A at the 40th Annual J.P. Morgan Healthcare Conference
WALTHAM, Mass. --(BUSINESS WIRE)--Dec. 29, 2021-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that Mark Enyedy , President and CEO, will present at the upcoming 40th Annual J.P.
View HTML
Toggle Summary ImmunoGen Presents Initial Findings From the Phase 1b/2 Study of IMGN632 in Combination With Vidaza® and Venclexta® in Relapsed/Refractory Acute Myeloid Leukemia at ASH
Triplet Data Demonstrating Manageable Safety Profile and Promising Anti-Leukemia Activity Highlighted in Oral Presentation Expansion Cohorts in Relapsed and Frontline AML Planned Data for IMGN632 in Three Frontline BPDCN Patients Also Presented in Poster Presentation Showing Clinical Complete
View HTML
Toggle Summary ImmunoGen Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
WALTHAM, Mass. --(BUSINESS WIRE)--Dec. 6, 2021-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced the closing of its previously announced underwritten public offering of 17,486,364 shares of its common
View HTML
Toggle Summary ImmunoGen Announces Pricing of Upsized Public Offering of Common Stock
WALTHAM, Mass. --(BUSINESS WIRE)--Dec. 2, 2021-- ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced the pricing of an underwritten public offering of 11,636,364 shares of its common stock at a price of $6.60
View HTML
Toggle Summary ImmunoGen Announces Proposed Public Offering of Common Stock
WALTHAM, Mass. --(BUSINESS WIRE)--Nov. 30, 2021-- ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that it intends to offer and sell, subject to market and other conditions, $175 million of shares of its
View HTML
Toggle Summary ImmunoGen Announces Positive Top-Line Results from Pivotal SORAYA Trial of Mirvetuximab Soravtansine in Ovarian Cancer
Trial Met Primary Endpoint with Confirmed Objective Response Rate of 32.4% Median Duration of Response at Data Cutoff is 5.9 Months Continued Demonstration of Favorable Tolerability Profile BLA Submission on Track for First Quarter of 2022 Conference Call to be Held at 8:00 a.m.
View HTML
Toggle Summary ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WALTHAM, Mass. --(BUSINESS WIRE)--Nov. 24, 2021-- ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that on November 22, 2021 the compensation committee of the Company’s Board of Directors granted
View HTML